Non-charged thiamine analogs as inhibitors of enzyme transketolase

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 2, 2008, Pages 509-512

  Thomas, Allen A ^a   De Meese, J ^a   Le Huerou, Y ^a   Boyd, Steven A ^a   Romoff, Todd T ^a   Gonzales, Steven S ^a   Gunawardana, Indrani ^a   Kaplan, Tomas ^a   Sullivan, Francis ^a   Condroski, Kevin ^a   Lyssikatos, Joseph P ^a   Aicher, Thomas D ^a   Ballard, Josh ^a   Bernat, Bryan ^a   DeWolf, Walter ^a   Han, May ^b   Lemieux, Christine ^a   Smith, Darin ^a   Weiler, Solly ^b   Wright, S Kirk ^b   Vigers, Guy ^a   Brandhuber, Barb ^a   more..

^a ARRAY BIOPHARMA INC   (United States)

^b AVEO ONCOLOGY   (United States)

Author keywords

Deazathiamine; Pyrazolothiamine; Pyrophosphate; Pyrophosphokinase; Thiamine; Thiazolone; Transketolase

Indexed keywords

AMINOPYRIDINE DERIVATIVE; COCARBOXYLASE; N3P TT; PHOSPHOTRANSFERASE; PROTEIN THTR1; PROTEIN THTR2; THIAMINE; THIAMINE DERIVATIVE; THIAMINE PYROPHOSPHOKINASE; THIAMINE THIAZOLONE; THIAMINE TRANSPORTER; THIAZOLE; TRANSKETOLASE; TRANSKETOLASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG PENETRATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; INHIBITION KINETICS; STRUCTURE ACTIVITY RELATION; SURFACE CHARGE;

ANIMALS; CATALYSIS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; MICE; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; THIAMINE; TRANSKETOLASE;

EID: 38149062719     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.098     Document Type: Article

References (20)

1. Cascante M., Centelles J.J., Veech R.L., Lee W.-N.P., and Boros L.G. Nutr. Cancer 36 (2000) 150
2. Boros L.G., Torday J.S., Lim S., Bassilian S., Cascante M., and Lee W.-N.P. Cancer Res. 60 (2000) 1183
3. Du M.X., Sim J., Fang L., Zheng Y., Koh S., Stratton J., Pons J., Wang J.J.-X., and Carte B. J. Biomol. Screen 9 (2004) 427
4. Solovjeva O.N., and Kochetov G.A. FEBS Lett. 462 (1999) 246
5. Boros L.G. Cancer Res. 58 (1998) 3188
6. Boros L.G., Puigjaner J., Cascante M., Lee W.-N.P., Brandes J.L., Bassilian S., Yusuf F.I., Williams R.D., Muscarella P., Melvin W.S., and Schirmer W.J. Cancer Res. 57 (1997) 4242
7. Kochetov G.A., Izotova A.E., and Meshalkina L.E. Biochem. Biophys. Res. Commun. 43 (1971) 1198
8. Voskoboyev A.I., and Ostrovsky Y.M. Ann. N.Y. Acad. Sci. 378 (1982) 161
9. Kandiko C.T., Smith D., and Yamamoto B.K. Biochem. Pharmacol. 37 (1988) 4375
10. Timm D.E., Liu J., Baker L.-J., and Harris R.A. J. Mol. Biol. 310 (2001) 195
11. Gutowski J.A., and Lienhard G.E. J. Biol. Chem. 251 (1976) 2863
12. Kluger R., Gish G., and Kauffman G. J. Biol. Chem. 259 (1984) 8960
13. Though it is possible that the cellular activity of non-pyrophosphates such as compound 3, N3P-TT, is a result of their direct interaction with TK, we believe it is much more likely that they are first converted by TPPK inside the cell into their pyrophosphate forms. The pyrophosphate binding to TK is greater by several orders of magnitude than the corresponding non-pyrophosphate analogs (Table 1).
14. Synthesis of starting material N3PT is presented in the preceding publication, Thomas, et al.
15. Hawksley D., Griffin D.A., and Leeper F.J. J. Chem. Soc., Perkin Trans. 1 (2001) 144
16. Fevig T.L., Phillips W.G., and Lau P.H. J. Org. Chem. 66 (2001) 2493
17. We would expect entropy differences related to structured water around the more polar thiazolone ring versus the thiophene ring. These entropy differences often lead to increased protein-ligand interactions. Andrews P.R. In: Wermuth C.G. (Ed). The Practice of Medicinal Chemistry (1996), Academic Press, London 349
18. Prior to performing the TPPK/Apo-TK assay, each compound was evaluated for its ability to be pyrophosphorylated by TPPK using thiamine as a control substrate. The extent of substrate pyrophosphorylation relative to thiamine pyrophosphorylation was determined prior to competition with TPP in inhibiting TK activity according to methods described in WO2005/095391.
19. Starting material (Z)-ethyl 5-(benzyloxy)-2-[(dimethylamino)methylene]-3-oxopentanoate was prepared in two steps from ethyl acetoacetate (50% yield). J. Org. Chem. 1986, 51, 106.
20. Either N-methylated pyrazole regioisomer can be prepared in a 3:1 regioselectivity by choice of methanol or diethyl ether as solvent. Menozi G., et al. J. Heterocycl. Chem. 24 (1987) 1669